aTyr Pharma, Inc. announced findings from an interim analysis of eight patients in the ongoing Phase 2 EFZO-CONNECT™ study, evaluating efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD). The analysis showed early positive signals across multiple skin assessment measures.
Three out of four efzofitimod-treated diffuse SSc-ILD patients demonstrated clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. All patients showed stable or improved mRSS, a measure of skin fibrosis.
Efzofitimod was generally safe and well tolerated at all doses in the interim analysis. The EFZO-CONNECT™ study is a 28-week randomized, double-blind, placebo-controlled, proof-of-concept study designed to enroll up to 25 patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.